PREVIEW: Merck & Co Inc (MRK) earnings due 03/Feb at 11:30GMT/06:30EST

Merck & Co Inc (MRK) Q4 2021 (USD): EPS (exp. 1.53/1.33 GAAP), Revenue (exp. 13.16bln)

KEY PHARMA SALES:

• Keytruda /MK-3475: (exp. 4.64bln)


• Gardasil/Gardasil 9: (exp. 1.4bln)


• Molnupiravir/MK-4482: (exp. 1.37bln)


• Januvia: (exp. 1.04bln)


• Proquad: (exp. 0.5bln)

REVENUE SEGMENTS:

• Animal Health: (exp. 1.36bln)


• Cardiovascular: (exp. 174.50mln)


• Diabetes: (exp. 1.31bln)


• Hospital Acute Care: (exp. 1.01bln)


• Immunology: (exp. 285.00mln)


• Neuroscience: (exp. 85.00mln)


• Oncology: (exp. 5.20bln)


• Other: (exp. 89.33mln)


• Other Pharma Sales: (exp. 560.50mln)


• Pharmaceutical: (exp. 12.94bln)


• Vaccines: (exp. 2.72bln)


• Virology: (exp. 1.20bln)

DIVIDEND:

• Qtrly Dividend: (exp. 0.67)


• FY Dividend: (exp. 2.61)

EPS GUIDANCE:

• Q1 2022 EPS View: (exp. 2.16/2.14 GAAP)


• FY 2022 EPS View: (exp. 8.15/7.81 GAAP)

REVENUE GUIDANCE:

• Q1 2022 Revenue View: (exp. 13.91bln)


• FY 2022 Revenue View: (exp. 50.18bln)

INDEX WEIGHT:

• 0.5% SPX weight


• 1.5% Dow weight


• Sector/Industry: Health Care/Pharmaceuticals

BROKER RATING:

• Avg Rating: 'Buy'


• Avg Price Target: USD 92.90


• Price Target Changes (last 30 days): 4 upward vs 8 downward

02 Feb 2022 - 17:00- Equities- Source: Newsquawk